deCODE genetics licenses developmental compound from Bayer AG
Expects to start enrollment for phase II clinical trial in myocardial infarction at the beginning of next year
17-Nov-2003 -
REYKJAVIK, Iceland - deCODE genetics announced that it has acquired an exclusive worldwide license from Bayer AG to develop and commercialize a small molecule compound. The compound is active against a key target, located within an inflammatory pathway, made by a gene isolated at deCODE that ...
acute myocardial infarction
Bayer
cholesterol
+11